Search

Your search keyword '"Khanfir, K."' showing total 141 results
Start Over Author "Khanfir, K."
141 results on '"Khanfir, K."'

1. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial

Author

Gut, P., Thum, P., Collon, J., Putora, P.M., Plasswilm, L., Sassowsky, M., Thalmann, G.N., Aebersold, D.M., Sumila, M., Kranzbühler, H., Zaugg, K., Papachristofilou, A., Zimmermann, F., Najafi, Y., Brown, M., Guckenberger, M., Wuttke, S., Reuter, C., Oehler, C., Zwahlen, D.R., Azinwi, N.C., Bosetti, D.G., Pesce, G., Tacacs, I., Bodis, S., Gomez, S., Khanfir, K., Behrensmeier, F., Beer, K., Messer, P., Hölscher, T., Baumann, M., Polat, B., Flentje, M., Lewitzki, V., Hildebrandt, G., Müller, A.C., Zips, D., Ghadjar, P., Wust, P., Budach, V., Ganswindt, U., Belka, C., Pinkawa, M., Eble, M.J., Berkovic, K., Stuschke, M., Ost, P., Vandaele, F., Ghadjar, Pirus, Hayoz, Stefanie, Bernhard, Jürg, Zwahlen, Daniel R., Hölscher, Tobias, Gut, Philipp, Polat, Bülent, Hildebrandt, Guido, Müller, Arndt-Christian, Plasswilm, Ludwig, Papachristofilou, Alexandros, Schär, Corinne, Sumila, Marcin, Zaugg, Kathrin, Guckenberger, Matthias, Ost, Piet, Reuter, Christiane, Bosetti, Davide G., Khanfir, Kaouthar, Gomez, Silvia, Wust, Peter, Thalmann, George N., and Aebersold, Daniel M.

Published
2021
Full Text
View/download PDF

2. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Author

Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., and Bouvier, C.

Published
2017
Full Text
View/download PDF

3. OC-0269 Early toxicity of SBRT for oligometastatic cancer patients in the EORTC/ESTRO OligoCare cohort

Author

Alongi, F., primary, Ricardi, U., additional, Scorsetti, M., additional, Liv, L., additional, Balermpas, P., additional, Lievens, Y., additional, Braam, P., additional, Jereczek-Fossa, B.A., additional, Stellamans, K., additional, Ratosa, I., additional, Widder, J., additional, Peulen, H., additional, Dirix, P., additional, Verbeke, L., additional, Ramella, S., additional, Hemmatazad, H., additional, Khanfir, K., additional, Geets, X., additional, Jeene, P., additional, Zilli, T., additional, Fournier, B., additional, Fortpied, C., additional, Oppong, F.B., additional, Ost, P., additional, and Guckenberger, M., additional

Published
2023
Full Text
View/download PDF

4. OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations

Author

Kroeze, S., primary, Pavic, M., additional, Stellamans, K., additional, Lievens, Y., additional, Becherini, C., additional, Scorsetti, M., additional, Alongi, F., additional, Ricardi, U., additional, Jereczek, B., additional, Westhoff, P., additional, But-Hadzic, J., additional, Widder, J., additional, Geets, X., additional, Bral, S., additional, Lambrecht, M., additional, Billiet, C., additional, Sirak, I., additional, Ramella, S., additional, Battista, I.G., additional, Benavente, S., additional, Zapatero, A., additional, Romero, F., additional, Zilli, T., additional, Khanfir, K., additional, Hemmatazad, H., additional, De Bari, B., additional, Klass, D., additional, Adnan, S., additional, Peulen, H., additional, Salinas Ramos, J., additional, Strijbos, M., additional, Popat, S., additional, Ost, P., additional, and Guckenberger, M., additional

Published
2023
Full Text
View/download PDF

5. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

Author

Kroeze, S.G.C., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek-Fossa, Barbara A., Westhoff, P.G., But-Hadzic, J., Widder, J., Geets, X., Bral, S., Lambrecht, M., Billiet, C., Sirak, I., Ramella, S., Giovanni Battista, I., Benavente, S., Zapatero, A., Romero, F., Zilli, T., Khanfir, K., Hemmatazad, H., Bari, B. De, Klass, D.N., Adnan, S., Peulen, H., Salinas Ramos, J., Strijbos, M., Popat, S., Ost, P., Guckenberger, M., Kroeze, S.G.C., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek-Fossa, Barbara A., Westhoff, P.G., But-Hadzic, J., Widder, J., Geets, X., Bral, S., Lambrecht, M., Billiet, C., Sirak, I., Ramella, S., Giovanni Battista, I., Benavente, S., Zapatero, A., Romero, F., Zilli, T., Khanfir, K., Hemmatazad, H., Bari, B. De, Klass, D.N., Adnan, S., Peulen, H., Salinas Ramos, J., Strijbos, M., Popat, S., Ost, P., and Guckenberger, M.

Abstract

Item does not contain fulltext, Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.

Published
2023

10. OC-0599 Factors associated with SBRT doses in oligometastatic disease: an EORTC/ESTRO OligoCare analysis

Author

Guckenberger, M., primary, Alongi, F., additional, Ricardi, U., additional, Scorsetti, M., additional, Balermpas, P., additional, Livi, L., additional, Lievens, Y., additional, Braam, P., additional, Jereczek- Fossa, B.A., additional, Stellamans, K., additional, Ratosa, I., additional, Peulen, H., additional, Widder, J., additional, Ramella, S., additional, Verbeke, L., additional, Dirix, P., additional, Khanfir, K., additional, Zilli, T., additional, Hemmatazad, H., additional, Jeene, P., additional, Ivaldi, G.B., additional, Clementel, E., additional, Fournier, B., additional, Fortpied, C., additional, and Ost, P., additional

Published
2022
Full Text
View/download PDF

12. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial

Author

Ghadjar, Pirus, primary, Hayoz, Stefanie, additional, Bernhard, Jürg, additional, Zwahlen, Daniel R., additional, Hölscher, Tobias, additional, Gut, Philipp, additional, Polat, Bülent, additional, Hildebrandt, Guido, additional, Müller, Arndt-Christian, additional, Plasswilm, Ludwig, additional, Papachristofilou, Alexandros, additional, Schär, Corinne, additional, Sumila, Marcin, additional, Zaugg, Kathrin, additional, Guckenberger, Matthias, additional, Ost, Piet, additional, Reuter, Christiane, additional, Bosetti, Davide G., additional, Khanfir, Kaouthar, additional, Gomez, Silvia, additional, Wust, Peter, additional, Thalmann, George N., additional, Aebersold, Daniel M., additional, Gut, P., additional, Thum, P., additional, Collon, J., additional, Putora, P.M., additional, Plasswilm, L., additional, Sassowsky, M., additional, Thalmann, G.N., additional, Aebersold, D.M., additional, Sumila, M., additional, Kranzbühler, H., additional, Zaugg, K., additional, Papachristofilou, A., additional, Zimmermann, F., additional, Najafi, Y., additional, Brown, M., additional, Guckenberger, M., additional, Wuttke, S., additional, Reuter, C., additional, Oehler, C., additional, Zwahlen, D.R., additional, Azinwi, N.C., additional, Bosetti, D.G., additional, Pesce, G., additional, Tacacs, I., additional, Bodis, S., additional, Gomez, S., additional, Khanfir, K., additional, Behrensmeier, F., additional, Beer, K., additional, Messer, P., additional, Hölscher, T., additional, Baumann, M., additional, Polat, B., additional, Flentje, M., additional, Lewitzki, V., additional, Hildebrandt, G., additional, Müller, A.C., additional, Zips, D., additional, Ghadjar, P., additional, Wust, P., additional, Budach, V., additional, Ganswindt, U., additional, Belka, C., additional, Pinkawa, M., additional, Eble, M.J., additional, Berkovic, K., additional, Stuschke, M., additional, Ost, P., additional, and Vandaele, F., additional

Published
2021
Full Text
View/download PDF

13. PD-0740 Real-world patient & treatment characteristics of oligometastatic disease: results of OligoCare

Author

Guckenberger, M., primary, Ricardi, U., additional, Scorsetti, M., additional, Balermpas, P., additional, Lievens, Y., additional, Alongi, F., additional, Livi, L., additional, Braam, P., additional, Jereczek-Fossa, B.A., additional, Stellamans, K., additional, Verbeke, L., additional, Peulen, H., additional, Khanfir, K., additional, Ramella, S., additional, Zilli, T., additional, Geets, X., additional, Hemmatazad, H., additional, Ivaldi, G.B., additional, Ratosa, I., additional, Jeene, P., additional, Fournier, B., additional, Fortpied, C., additional, and Ost, P., additional

Published
2021
Full Text
View/download PDF

17. PO-0956: Neuroendocrine Tumors of the Breast: an international series of the Rare Cancer Network

Author

Grellier-Adedjouma, N., primary, Paix, A., additional, Franco, P., additional, Kirova, Y.M., additional, De Bari, B., additional, Pasquier, D., additional, Meijer, H., additional, Oksüz, D.C., additional, Peignaux-Casasnovas, K., additional, Huguet, F., additional, De Caluwé, A., additional, Khanfir, K., additional, Vargas, A., additional, Thariat, J., additional, Vargo, J.A., additional, Ozsahin, E.M., additional, and Belkacemi, Y., additional

Published
2020
Full Text
View/download PDF

19. Clinical Outcomes of Rectal Squamous Cell Carcinomas Treated with Chemoradiotherapy with or Without Surgery: A Rare Cancer Network Study.

Author

De Bari, B., primary, Aloi, D., additional, Lemanski, C., additional, Hallemeier, C.L., additional, Touboul, E., additional, Qi, S., additional, Christie, D., additional, Vees, H., additional, Shulman, K., additional, Atasoy, B.M., additional, Sefik, I., additional, Micke, O., additional, Servagi Vernat, S., additional, and Khanfir, K., additional

Published
2018
Full Text
View/download PDF

20. OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial

Author

Ghadjar, P., primary, Hayoz, S., additional, Genitsch, V., additional, Zwahlen, D., additional, Hölscher, T., additional, Gut, P., additional, Guckenberger, M., additional, Hildebrandt, G., additional, Müller, A.C., additional, Putora, M., additional, Papachristofilou, A., additional, Stalder, L., additional, Biaggi-Rudolf, C., additional, Sumila, M., additional, Kranzbühler, H., additional, Najafi, Y., additional, Ost, P., additional, Azinwi, N., additional, Reuter, C., additional, Bodis, S., additional, Khanfir, K., additional, Budach, V., additional, Aebersold, D., additional, Perren, A., additional, and Thalmann, G., additional

Published
2017
Full Text
View/download PDF

22. Corrigendum: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

Author

Feilchenfeldt, J, Varga, Z, Siano, M, Grabsch, H I, Held, U, Schuknecht, B, Trip, A, Hamaguchi, T, Gut, P, Balague, O, Khanfir, K, Diebold, J, Jochum, W, Shoji, H, Kushima, R, Wagner, D, Shimada, Y, Cats, A, Knuth, A, Moch, H, Aebi, S, Hofer, S, and University of Zurich

Subjects
10049 Institute of Pathology and Molecular Pathology, 610 Medicine & health, 2730 Oncology, 1306 Cancer Research
Published
2015

23. Radiation Therapy for Extracranial Hemangiopericytoma/Solitary Fibrous Tumor: A Study From the Rare Cancer Network

Author

Krengli, M., Bari, B. De, Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Krengli, M., Bari, B. De, Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., and Cena, T.

Abstract

Item does not contain fulltext

Published
2016

24. Radiation Therapy for Extracranial Hemangiopericytoma/Solitary Fibrous Tumor: A Study From the Rare Cancer Network

Author

Krengli, M., primary, De Bari, B., additional, Villa, S., additional, Kaanders, J.H.A.M., additional, Torrente, S., additional, Pasquier, D., additional, Thariat, J.O., additional, Myroslav, L., additional, Sole, C.V., additional, Dincbas, H.F., additional, Habboush, J.Y., additional, Zilli, T., additional, Dragan, T., additional, Khanfir, K., additional, Ugurluer, G., additional, and Cena, T., additional

Published
2016
Full Text
View/download PDF

25. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).

Author

Feilchenfeldt, J, Varga, Z, Siano, M, Grabsch, H I, Held, U, Schuknecht, B, Trip, A, Hamaguchi, T, Gut, P, Balague, O, Khanfir, K, Diebold, J, Jochum, W, Shoji, H, Kushima, R, Wagner, D, Shimada, Y, Cats, A, Knuth, A, Moch, H, Aebi, S, Hofer, S, Feilchenfeldt, J, Varga, Z, Siano, M, Grabsch, H I, Held, U, Schuknecht, B, Trip, A, Hamaguchi, T, Gut, P, Balague, O, Khanfir, K, Diebold, J, Jochum, W, Shoji, H, Kushima, R, Wagner, D, Shimada, Y, Cats, A, Knuth, A, Moch, H, Aebi, S, and Hofer, S

Abstract

BACKGROUND Gastro-oesophageal adenocarcinomas rarely metastasize to the central nervous system (CNS). The role of the human epidermal growth factor receptor 2 (HER2) in patients with these cancers and CNS involvement is presently unknown. PATIENTS AND METHODS A multicentre registry was established to collect data from patients with gastro-oesophageal adenocarcinomas and CNS involvement both retrospectively and prospectively. Inclusion in the study required a predefined clinical data set, a central neuro-radiological or histopathological confirmation of metastatic CNS involvement and central assessment of HER2 by immunohistochemistry (IHC) and in situ hybridisation (ISH). In addition, expression of E-cadherin and DNA mismatch repair (MMR) proteins were assessed by IHC. RESULTS One hundred patients fulfilled the inclusion criteria. The population's median age was 59 years (interquartile range: 54-68), of which 85 (85%) were male. Twenty-five patients were of Asian and 75 of Caucasian origin. HER2 status was positive in 36% (95% CI: 26.6-46.2) of cases. Median time from initial diagnosis to the development of brain metastases (BMets) or leptomeningeal carcinomatosis (LC) was 9.9 months (95% CI: 8.5-15.0). Median overall survival from diagnosis was 16.9 months (95% CI: 14.0-20.7) and was not related to the HER2 status. E-cadherin loss was observed in 9% of cases and loss of expression in at least one DNA MMR proteins in 6%. CONCLUSIONS The proportion of a positive HER2 status in patients with gastro-oesophageal adenocarcinoma and CNS involvement was higher than expected. The impact of anti-HER2 therapies should be studied prospectively.British Journal of Cancer advance online publication 27 August 2015; doi:10.1038/bjc.2015.279 www.bjcancer.com.

Published
2015

26. Stereotactic body radiation therapy in stage I inoperable lung cancer: from palliative to curative options

Author

Boujelbene, N., Elloumi, F., Kamel, M.E., Abeidi, H., Matzinger, O., Mirimanoff, R.O., and Khanfir, K.

Subjects
respiratory tract diseases
Abstract

Surgery has historically been the standard of care for operable stage I non-small cell lung cancer (NSCLC). However, nearly one-quarter of patients with stage I NSCLC will not undergo surgery because of medical comorbidity or other factors. Stereotactic ablative radiotherapy (SABR) is the new standard of care for these patients. SABR offers high local tumour control rates rivalling the historical results of surgery and is generally well tolerated by patients with both peripheral and centrally located tumours. This article reviews the history of SABR for stage I NSCLC, summarises the currently available data on efficacy and toxicity, and describes some of the currently controversial aspects of this treatment.

Published
2013

27. Pure seminoma: A review and update

Author

Boujelbene, N., Cosinschi, A., Khanfir, K., Bhagwati, S., Herrmann, E., Mirimanoff, R.O., Ozsahin, M., and Zouhair, A.

Abstract

Pure seminoma is a rare pathology of the young adult, often discovered in the early stages. Its prognosis is generally excellent and many therapeutic options are available, especially in stage I tumors. High cure rates can be achieved in several ways: standard treatment with radiotherapy is challenged by surveillance and chemotherapy. Toxicity issues and the patients' preferences should be considered when management decisions are made. This paper describes firstly the management of primary seminoma and its nodal involvement and, secondly, the various therapeutic options according to stage.

Published
2011

28. Erratum: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

Author

Feilchenfeldt, J, primary, Varga, Z, additional, Siano, M, additional, Grabsch, H I, additional, Held, U, additional, Schuknecht, B, additional, Trip, A, additional, Hamaguchi, T, additional, Gut, P, additional, Balague, O, additional, Khanfir, K, additional, Diebold, J, additional, Jochum, W, additional, Shoji, H, additional, Kushima, R, additional, Wagner, D, additional, Shimada, Y, additional, Cats, A, additional, Knuth, A, additional, Moch, H, additional, Aebi, S, additional, and Hofer, S, additional

Published
2015
Full Text
View/download PDF

29. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)

Author

Feilchenfeldt, J, primary, Varga, Z, additional, Siano, M, additional, Grabsch, H I, additional, Held, U, additional, Schuknecht, B, additional, Trip, A, additional, Hamaguchi, T, additional, Gut, P, additional, Balague, O, additional, Khanfir, K, additional, Diebold, J, additional, Jochum, W, additional, Shoji, H, additional, Kushima, R, additional, Wagner, D, additional, Shimada, Y, additional, Cats, A, additional, Knuth, A, additional, Moch, H, additional, Aebi, S, additional, and Hofer, S, additional

Published
2015
Full Text
View/download PDF

31. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study.

Author

Vos, Bertrand, Rozema, T, Miller, Richard, Hendlisz, Alain, Van Laethem, Jean-Luc, Khanfir, K, Weber, Donald, El Nakadi, Issam, Van Houtte, Paul, Vos, Bertrand, Rozema, T, Miller, Richard, Hendlisz, Alain, Van Laethem, Jean-Luc, Khanfir, K, Weber, Donald, El Nakadi, Issam, and Van Houtte, Paul

Abstract

Small cell carcinoma of the esophagus (SCCE) is a rare and aggressive malignant tumor with a poor prognosis. The aims of this retrospective study were to analyze the epidemiology, clinical characteristics, and treatment outcomes of these patients. Between 1994 and 2004, 24 patients with SCCE from several centers were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment, and outcome. SCCE occurs in the sixth decade: median age (interquartile range [IQR]): 65 (59-69) years with a male predominance (63%). The most common complaining symptoms were rapidly progressive dysphagia (79%), weight loss (54%), and retrosternal/epigastric pain (46%). The tumor arises primarily in the middle (52%) or in the lower (35%) third of the esophagus. History of tobacco and alcohol exposure was present in 90% and 70% of case, respectively. Extensive disease was present in 13 cases (54%) at initial diagnosis. The overall median survival (IQR) was 11 (8-20) months for all 24 patients, and the 2-year overall survival was 25.1%. Four patients were alive more than 2 years after treatment. Chemotherapy increased the survival compared with symptomatic management in extensive disease (median survival [IQR]: 9.5 [6-14] vs. 6 [4-7] months, P= 0.05). In limited disease, concurrent chemo-radiotherapy was more effective than non-concurrent treatment (median survival [IQR]: 36 [14-93] vs. 11 [9-15] months, P= 0.04). Two patients were treated by surgery and chemoradiation therapy with a survival of 35 and 66 months. Chemotherapy is the cornerstone of treatment of SCCE in all stage. For limited disease SCCE, concurrent chemo-radiotherapy is the primary choice compared with sequential approach. The role of surgery was not assessable in our study., Journal Article, Multicenter Study, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2011

49. Clinical Outcomes of Rectal Squamous Cell Carcinomas Treated with Chemoradiotherapy with or Without Surgery: A Rare Cancer Network Study

Author

H. Vees, S. Qi, K. Khanfir, E. Touboul, S. Servagi Vernat, O. Micke, I. Sefik, Beste M. Atasoy, D. Christie, C. Lemanski, B. De Bari, C.L. Hallemeier, K. Shulman, D. Aloi, De Bari, B., Aloi, D., Lemanski, C., Hallemeier, C. L., Touboul, E., Qi, S., Christie, D., Vees, H., Shulman, K., Atasoy, B. M., Sefik, I., Micke, O., Vernat, S. Servagi, and Khanfir, K.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Cell, Rare cancer, medicine.anatomical_structure, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, Chemoradiotherapy
Published
2018
Full Text
View/download PDF

50. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E 2 -RADIatE OligoCare cohort.

Author

Alongi F, Nicosia L, Ricardi U, Scorsetti M, Greto D, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Simek IM, Peulen H, Dirix P, Verbeke L, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Fortpied C, Boakye Oppong F, Ost P, and Guckenberger M

Subjects
Humans, Female, Male, Aged, Prospective Studies, Middle Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung pathology, Breast Neoplasms radiotherapy, Breast Neoplasms pathology, Adult, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Registries, Colorectal Neoplasms pathology, Radiosurgery adverse effects, Radiosurgery methods, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Neoplasm Metastasis
Abstract

Aim: To evaluate acute toxicity at 6 months after stereotactic body radiotherapy (SBRT) in patients with oligometastatic cancer within the OligoCare cohort., Material and Methods: OligoCare is a prospective, registry-based, single-arm, observational study that aims to report prospective real-world data of patients with oligometastases from solid cancer treated with SBRT (NCT03818503). Primary tumor included non-small cell lung cancer (NSCLC), breast cancer (BC), colorectal cancer (CRC), and prostate cancer (PC). This analysis addresses a secondary endpoint of the trial, acute toxicity within 6 months after SBRT., Results: Out of 1,597registered patients, 1'468 patients were evaluated for acute toxicity. Globally, 290 (20 %) had NSCLC primary disease, 227 (16 %) had BC, 293 (20 %) had CRC, and 658 (45 %) had PC. Concomitant systemic treatment was administered in 527 (35.9 %) patients. According to the EORTC/ESTRO oligometastatic disease (OMD) classification, 828 (56 %) patients had de novo OMD, 464 (32 %) repeat OMD, and 176 (12 %) induced OMD. Acute grade ≥ 3 SBRT related adverse events were reported in 8 (0.5 %) patients, including 2 (0.1 %) fatal AEs. In particular, 6 (0.4 %) grade 3 events were: 1 empyema, 1 pneumonia, 1 radiation pneumonitis, 1 radiation skin injury, 1 decreased appetite, and 1 bone pain. Among those 2 occurred in NSCLC patients, 2 in BC patients, and 1 in CRC and PC patients each. The two (0.1 %) grade 5 toxicity were represented by: pneumonitis and cerebral hemorrhage., Conclusion: OligoCare is the largest prospective registry cohort on oligometastatic disease. Acute toxicity within 6 months was low, confirming the safety of SBRT in the treatment of oligometastases., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results